E. Kúdela, M. Ňachajová, J. Višňovský, J. Danko
SUMMARY
Myomas are considered to be the most common benign tumours in women. The aetiology
and biology of uterine myomas are still questionable, but hormones play
a significant role in this process. Selective progesterone receptor modulators (SPRMs)
are a new class of progesterone receptor ligands showing tissue-specific activity
on target cells. UPA is a representative of the SPRM group used for preoperative
and intermittent treatment of moderate and severe myoma-associated symptoms
in reproductive-age women. Together with other SPRMs, it significantly reduces
menstrual bleeding and volume of myomas. PEARL studies have shown the efficacy
of UPA in the treatment and long-term management of uterine myomas and severe
menstrual bleeding.